Compare SAH & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SAH | JANX |
|---|---|---|
| Founded | 1997 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.8B |
| IPO Year | 1997 | 2021 |
| Metric | SAH | JANX |
|---|---|---|
| Price | $63.35 | $13.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 12 |
| Target Price | ★ $80.75 | $60.27 |
| AVG Volume (30 Days) | 179.3K | ★ 2.3M |
| Earning Date | 02-11-2026 | 11-06-2025 |
| Dividend Yield | ★ 2.41% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.73 | N/A |
| Revenue | ★ $15,178,100,000.00 | $10,000,000.00 |
| Revenue This Year | $7.94 | N/A |
| Revenue Next Year | $3.35 | N/A |
| P/E Ratio | $16.86 | ★ N/A |
| Revenue Growth | ★ 9.09 | N/A |
| 52 Week Low | $52.00 | $13.28 |
| 52 Week High | $89.62 | $61.59 |
| Indicator | SAH | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 47.64 | 26.48 |
| Support Level | $60.85 | $13.82 |
| Resistance Level | $64.03 | $14.49 |
| Average True Range (ATR) | 1.48 | 0.47 |
| MACD | -0.14 | 0.36 |
| Stochastic Oscillator | 49.80 | 4.69 |
Sonic Automotive is one of the largest auto dealership groups in the United States. The company has 108 franchised stores in 18 states, primarily in metropolitan areas in California, Texas, and the Southeast, plus 18 EchoPark used-vehicle stores, 16 collision centers, and 14 powersports locations. The franchise stores derive revenue from new and used vehicles plus parts and collision repair, finance, insurance, and wholesale auctions. Luxury and import dealerships make up about 86% of franchise new-vehicle revenue, while Honda, BMW, Mercedes, and Toyota constitute about 59% of new-vehicle revenue. BMW is the largest brand at about 25%. 2024's revenue was $14.2 billion, with Texas and California comprising 51% of the total. EchoPark's portion was $2.1 billion.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.